病例討論~張盛皇、王照元-癌思停(Bevacizumab)治療轉移性結直腸癌導致之偽動脈瘤破裂

1. 簡介:
Bevacizumab( Avast-
in )
Bevacizumab
0.03%
(Bevacizumab)
病例報告:
65
(cT4aN2aM1b, Stage: IVB)
2016/04/29
(FOLFIRI) 2016/5/13
(Bevacizumab)
FOLFIRI (Bevacizumab)

2. (
)
( )
討論:
(Bevacizumab)
42902
11
0.03%
6 12
(Bevacizumab)
( )
Cartwright T, Hainsworth J, Heim W, Berlin J,
Bevacizumab plus irinotecan, fluorouracil, and
leucovorin for metastatic colorectal cancer. N
Patel T, Hamm JT, Hecht JR, et al. Addition
of bevacizumab to bolus fluorouracil and
leucovorin in first-line metastatic colorectal
cancer: Results of a randomized phase II trial.
patients treated with bevacizumab combination

3. Bevacizumab in the management
S, Kretzschmar A, Michael M,
Dibartolomeo M, et al. Safety and
efficacy of first line bevacizumab
and fluoropyrimidines in metastatic
patients with cancer treated with
bevacizumab: a meta-analysis of